Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHTS study of LCIG versus optimized medical treatment for non-motor symptoms in advanced Parkinson's disease
2014-004865-26Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levodopa and carbidopa in Parkinson's disease (PD) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Non-Motor Symptoms Scale total score and Modified Parkinson's Disease Sleep Scale total score. Started May 2015; status: terminated.
02
Drugs
levodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2014-004865-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004865-26.